Navigation Links
Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients
Date:10/4/2007

- HeFH Patients on Maximally Tolerated Lipid-Lowering Therapies Experienced 46% Further Reductions in LDL-C when Treated with 300 mg/week ISIS 301012

for 13 Weeks - Study Presented in Poster Session Today at DALM Symposium in New York

City - Isis Will Host a Conference Call on Monday, October 8, at 8:00 a.m. E.T.

at http://www.isispharm.com

CARLSBAD, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced new results from its Phase 2 clinical trial of ISIS 301012 in patients with heterozygous familial hypercholesterolemia (HeFH) on stable maximally tolerated lipid-lowering therapies presented in a poster session today at the Drugs Affecting Lipid Metabolism (DALM) XVI International Symposium in New York City. These results will also be presented by Dr. John J.P. Kastelein in an oral session at DALM on Saturday at 3:45 p.m. E.T., and Isis will host a conference call Monday morning at 8:00 a.m. E.T. to further discuss the results.

In a randomized, double-blind, placebo-controlled study, HeFH patients being treated with maximally tolerated lipid-lowering therapies were treated with ISIS 301012 for 6 or 13 weeks. Median baseline LDL-C levels for the dose cohorts ranged from 159 - 204 mg/dL. ISIS 301012 add-on treatment produced potent, dose-dependent, prolonged reductions in all atherogenic lipids, and results were consistent with those reported for patients with routine high cholesterol. Furthermore, this study confirmed that ISIS 301012 treatment results in meaningful reductions in Lp(a), another important predictor of
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- The quantum dot market report analyzes the ecosystem of ... the product includes medical devices, display, and others. The others ... energy storage, QD laser, and transistor. The application segment covers ... market. The report also provides the geographic view for major ... Europe , Asia-Pacific (APAC), ...
(Date:9/2/2015)... YORK , Sept. 2, 2015   About ... the most common laboratory technologies that is used for ... antibodies in solution. ELISA test uses various types of ... phosphatases and the result is detected by photometry or ... the treatment of various infectious diseases such as HIV, ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ( ... Regulatory Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... will provide a detailed overview of the key areas of ... Hong Kong , Macau ... - All important aspects of gaining and maintaining ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... ... of its efforts to expand awareness of the importance of medical ... America (PhRMA) is announcing today the addition of seven new member ... membership to include an impressive list of progressive companies that represent ...
... ... , ... Will Use BrainTrack,s College Campus Data to Enhance Elsevier Evolve,Website Registrations , ... information products and services, and BrainTrack,( http://www.braintrack.com ), the widely referenced higher-education,directory, announced ...
Cached Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... ProScrub ... easily create back & forth, flicker, repeat, and custom speed effects without the use ... and the speed of effect. ProScrub tools are perfect complements to energetic video ...
(Date:9/3/2015)... ... ... Mum n Me is pleased to announce the launch of its ... maximum protection from sun exposure, wind, bugs, and germs. The Mum n Me Baby ... keeping the cover securely in place. The new car seat cover is made with ...
(Date:9/3/2015)... ... ... new cases of prostate cancer are reported each year, along with 27,540 deaths attributed to ... lifetime. While only one man in 10,000 will typically get prostate cancer under age 40, ... American Cancer Society. , Prostate cancer is the second leading cause ...
(Date:9/3/2015)... ... September 03, 2015 , ... The partnership will ... and technical support services to promote LodonalTM in Nigeria. The distribution will become ... efficacy and safety of the product. , Managing Director, Fidson Healthcare Plc, Dr ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2
... 2009)Fox Chase Cancer Center researchers report that a combination ... inhibitor of the HER2 receptor (ErbB2) appears active in ... on previous trastuzumab based therapies. More than one-quarter ... their tumors shrink on the combination therapy. , ...
... Laboratories, Inc. (Nasdaq: IDXX ), announced today that ... Annual Growth Stock Conference. Jonathan Ayers, Chairman and CEO, is ... June 9, 2009 at 10:50 a.m. (Central Time), at the ... audio webcast of the presentation through a link on the ...
... Darwin National,Assurance Company, a member company of ... AWH ), today announced that Becky Cox has ... role, Ms. Cox will,be responsible for the continued ... alongside Fred Bautista, Vice,President, Business Development, Healthcare. , ...
... Monday, June 1, 20091:30 to 2:30 p.m. Rooftop garden offers patients quiet haven, conservatory features ... Aurora St. Luke,s Medical Center is dedicating the Vince, ... Funds Healing Garden and the Agnes and, ... Monday, June 1, 1:30 to 2:30 p.m., WHERE: ...
... Francisco-to-Los Angeles ride May 31SAN FRANCISCO and LOS ANGELES, ... states and 14 nations will stream out of San ... as participants in the colorful and emotional AIDS/LifeCycle, the ... to raise more than $10 million to support vital ...
... May 28 (HealthDay News) --Should it worry you that there ... , Not especially, when you consider that there are 44 ... , This information comes to you from scientists at the ... same techniques that enabled them to map the human genetic ...
Cached Medicine News:Health News:Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 3Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 3Health News:Study Finds Multitude of Bacteria on Human Skin 2Health News:Study Finds Multitude of Bacteria on Human Skin 3
... ART Aerosol Resistant Tips offer a safe ... Tips are designed for applications such as ... In addition, ART Tips are excellent for ... forensic studies. ART Tips prevent aerosol contaminants ...
Inquire...
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
Medicine Products: